CytomX Therapeutics Inc. (CTMX)
0.66
-0.02 (-2.54%)
At close: Mar 03, 2025, 11:56 AM
No 1D chart data available
| Bid | 0.66 |
| Market Cap | 51.72M |
| Revenue (ttm) | 116.45M |
| Net Income (ttm) | 12.72M |
| EPS (ttm) | 0.16 |
| PE Ratio (ttm) | 4.13 |
| Forward PE | -2.01 |
| Analyst | Hold |
| Ask | 0.66 |
| Volume | 198,962 |
| Avg. Volume (20D) | 971,782 |
| Open | 0.67 |
| Previous Close | 0.68 |
| Day's Range | 0.65 - 0.67 |
| 52-Week Range | 0.65 - 5.85 |
| Beta | 1.00 |
About CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2015
Employees 120
Stock Exchange NASDAQ
Ticker Symbol CTMX
Website https://www.cytomx.com
Analyst Forecast
According to 6 analyst ratings, the average rating for CTMX stock is "Hold." The 12-month stock price forecast is $5.79, which is an increase of 776.08% from the latest price.
Buy 50.00%
Hold 50.00%
Sell 0.00%
Next Earnings Release
CytomX Therapeutics Inc. is scheduled to release its earnings on Mar 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+9%
CytomX Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
9 months ago
-51.31%
CytomX Therapeutics shares are trading lower, pulling back after surging after hours Thursday following initial data from the ongoing CX-904 Phase 1a dose escalation clinical study.
